Impact of lung surfactant therapy on chronic lung diseases in premature infants

Area of Science:

• Neonatal Medicine
• Pediatric Pulmonology
• Respiratory Physiology

Background:

• Bronchopulmonary dysplasia (BPD) and chronic lung disease are significant complications of preterm birth.
• These conditions affect the developing lungs of premature infants, leading to long-term respiratory issues.
• Historically, BPD has been a major concern in neonatal intensive care units.

Purpose of the Study:

• To review the historical evolution of Bronchopulmonary dysplasia (BPD) since its initial description.
• To analyze the impact of surfactant replacement therapy on the incidence and clinical presentation of BPD.
• To discuss the emergence of a new phenotype of chronic lung disease in surfactant-treated premature infants.

Main Methods:

• Literature review of studies on BPD and surfactant therapy.
• Analysis of historical data and clinical observations.
• Comparative assessment of BPD characteristics before and after surfactant therapy introduction.

Main Results:

• Surfactant replacement therapy has influenced the incidence and characteristics of BPD.
• A distinct form of chronic lung disease is now observed in premature infants treated with surfactant, even without prior acute lung injury.
• The evolution of BPD suggests changing patterns in neonatal respiratory care.

Conclusions:

• Surfactant therapy has altered the landscape of chronic lung disease in premature infants.
• Understanding the evolving nature of BPD is crucial for optimizing neonatal respiratory support.
• Further research is needed to characterize and manage this new form of chronic lung disease.